Tribe, Drugmaker Ask Justices To Overturn Bar On Sovereign Immunity IPR Protection

Mealey's (January 15, 2019, 2:45 PM EST) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals’ ruling that an Indian tribe’s sovereign immunity cannot shield a drug company from inter partes review (IPR) of patents should be vacated because it conflicts with U.S. Supreme Court precedent, a tribe and drugmaker argue in their petition for a writ of certiorari, docketed Jan. 11 with the high court (Saint Regis Mohawk Tribe, et al. v. Mylan Pharmaceuticals Inc., et al., No. 18-899, U.S. Sup.)....